1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Medical - Specialties
Proteome Sciences plc

Proteome Sciences plc

PMSNF
Proteome Sciences plcUS flagOther OTC
0.02
USD
- -
- -
5.78MMarket Cap
Proteome Sciences plc
PMSNF
(Other OTC)

Recent

price

0.02

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.06
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.02
0.02
0.02
0.03
0.02
0.02
- -
Revenue per Share
0.03
-0.02
-0.02
-0.02
-0.02
-0.01
-0.01
-0.01
- -
- -
- -
- -
- -
-0.01
-0.01
- -
Basic EPS, GAAP
0.02
-0.03
-0.02
-0.01
-0.02
-0.01
-0.01
-0.01
- -
- -
0.01
- -
0.01
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.29
-0.26
-0.29
-0.3
-0.29
-0.29
-0.28
-0.23
-0.24
-0.24
-0.23
-0.23
-0.23
-0.24
-0.25
- -
Book Value per Share
0.02
- -
-0.03
-0.03
-0.02
-0.02
-0.02
-0.02
-0.03
-0.03
-0.03
-0.02
-0.02
-0.02
-0.04
- -
Tangible Book Value per Share
164
192
192
194
211
221
236
295
295
295
295
295
295
295
295
- -
Basic Weighted Avg Shares
10
1
1
2
2
2
3
3
3
5
5
5
8
5
5
4
Sales/Revenue/Turnover
47.53
-425.13
-367.83
-157.84
-255.8
-163.71
-97.92
-53.49
-44.93
6.42
11.55
8.03
22.21
-32.24
-48.15
-70.98
Operating Margin (%)
- -
- -
- -
- -
- -
- -
1
- -
- -
- -
- -
- -
- -
- -
1
1
Depreciation Expense
5
-4
-4
-3
-4
-3
-2
-2
-1
- -
- -
- -
1
-2
-3
-3
Net Income, GAAP
0.57
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
38.98
- -
- -
- -
- -
Effective Tax Rate (%)
45.72
-387.53
-368.93
-147.39
-228.44
-144.42
-83.09
-73.88
-43.06
3.2
6.21
1.4
17.03
-48.59
-69.7
-81.5
Profit Margin (%)
2
-2
-5
-7
-6
-6
-4
-7
-8
-8
-7
-7
-6
-8
-11
-14
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
2
1
1
LT Debt
7
3
-1
-2
-1
-1
- -
-3
-4
-4
-3
-3
-1
-3
-7
-10
Total Equity
58.3
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
3.04
- -
- -
- -
- -
Return on Invested Capital (%)
-12.05
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-0.44
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
154.32%
67.31%
44.06%
Free Cash Flow
-445.84%
-6.58%
-86.38%
Net Income, GAAP
134.22%
281.92%
-10.13%
Sales/Revenue/Turnover
11.23%
-0.34%
-23.14%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
5
2024
- -
- -
- -
- -
5
2025
- -
- -
- -
- -
4

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.01
2024
- -
- -
- -
- -
-0.01
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Contec Medical Systems Co.,Ltd (300869.SZ)
Coloplast A/S (CBHD.DE)
Span Divergent Limited (SDL.BO)
Koninklijke Philips N.V. (PHG)
Edwards Lifesciences Corporation (EW.SW)
IDenta Corp. (IDTA)
Business
Proteome Sciences plc is a specialist provider of contract proteomics services focused on protein biomarker research and development. The company offers proprietary high-sensitivity proteomic technologies, including multiplexed Tandem Mass Tag (TMT) based mass spectrometry reagents and services for the quantitation and characterization of protein and peptide biomarkers in complex biological samples. Key products include TMT and TMTpro chemical reagents for multiplex quantitative proteomics, which are manufactured under exclusive license and sold to partners such as Thermo Fisher Scientific. Proteome Sciences also provides contract research services including biomarker discovery, validation, immunopeptidomics, single-cell proteomics, and data-independent acquisition (DIA) workflows to support drug discovery, clinical trials, and biomarker identification across major human diseases. The company operates laboratories and offers services primarily in the United Kingdom, United States, and Europe. Recent major developments involve the expansion of its US laboratory to meet significant demand from US West Coast biopharmaceutical clients and the addition of DIA label-free proteomics to service offerings with ongoing client projects underway. In 2024, Proteome Sciences secured substantial Good Clinical Laboratory Practice (GCLP) contracts with US biopharmaceutical firms, notably winning over $1 million contracts linked to ongoing clinical trials. The company launched its first commercial single-cell proteomics services and advanced immunopeptidomics capabilities. It is actively pursuing licensing partnerships for newly developed DXT reagents to enhance its multiplexing technology portfolio. Additionally, Proteome Sciences entered into new loan agreements totaling £1 million with Vulpes Investment Management and executive leadership to support ongoing operations and growth initiatives. Founded in 2001 and headquartered in the United Kingdom, Proteome Sciences focuses on applied proteomics for diagnostic, prognostic, and therapeutic biomarker applications. Its target markets include pharmaceutical and biopharmaceutical companies, academic research institutions, and clinical trial organizations. The company continues to invest in internal research and development while securing orders primarily from US and European clients. Its proprietary TMT reagents and contract research services position Proteome Sciences as a critical partner in the global life sciences and precision medicine sectors. Proteome Sciences plc maintains a portfolio of proprietary technologies for multiplex protein quantitation and biomarker analysis, leveraging deep scientific expertise and collaborative strategic alliances to drive innovation in proteomics-based drug discovery and development. This corporate profile reflects the latest publicly available information as of late 2025.